Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing's CANbridge Raises $25 Million for Immuno-Oncology Drugs

publication date: May 23, 2017
CANbridge Life Sciences of Beijing completed a $25 million Series B round from China investors. The company, which has raised $40 million to date, said it expects to announce additional strategic transactions this year. CANbridge will use the money to fund clinical trials of its two lead candidates, both of which are oncology drugs. CANbridge focuses on developing Western drug candidates in China and North Asia. Lapam Capital, a Beijing life science VC, led the round and was joined by other China life science investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital